STRATA Skin Sciences Files 8-K

TL;DR

STRATA Skin Sciences filed an 8-K, likely containing financial updates and disclosures.

AI Summary

On July 23, 2024, STRATA Skin Sciences, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and the inclusion of Financial Statements and Exhibits. No specific financial figures or new material events were detailed in the provided excerpt.

Why It Matters

This 8-K filing indicates STRATA Skin Sciences is providing updated disclosures and financial information to the SEC, which is standard practice for public companies.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report for disclosures and exhibits, not indicating any immediate adverse events.

Key Players & Entities

• STRATA Skin Sciences, Inc. (company) — Registrant
• MELA SCIENCES, INC. (company) — Former Company Name
• ELECTRO OPTICAL SCIENCES INC (company) — Former Company Name
• July 23, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value per share SSKN The NASDAQ
• $3.16 — n stock at an average purchase price of $3.16 per share for total gross proceeds of $
• $2.10 million — 6 per share for total gross proceeds of $2.10 million. The common stock offered in the regist

Filing Documents

• ef20032877_8k.htm (8-K) — 29KB
• ef20032877_ex99-1.htm (EX-99.1) — 8KB
• image0.jpg (GRAPHIC) — 6KB
• 0001140361-24-033878.txt ( ) — 192KB
• sskn-20240723.xsd (EX-101.SCH) — 4KB
• sskn-20240723_lab.xml (EX-101.LAB) — 21KB
• sskn-20240723_pre.xml (EX-101.PRE) — 16KB
• ef20032877_8k_htm.xml (XML) — 4KB

01

Item 7.01. Regulation FD Disclosure. On July 23, 2024, STRATA Skin Sciences, Inc. (the "Company") issued a press release announcing the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the issuance and sale of 665,136 shares of its common stock at an average purchase price of $3.16 per share for total gross proceeds of $2.10 million. The common stock offered in the registered direct offering was offered and sold by the Company pursuant to a "shelf" registration statement on Form S-3 (Registration No. 333-258814) previously filed with the Securities and Exchange Commission (SEC) on August 13, 2021 and which was declared effective by the SEC on October 15, 2021 and subsequently amended on June 24, 2024. Insiders and previously existing shareholders participated in the completed direct offering. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth in this item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. The following press release is furnished as an exhibit to this Current Report on Form 8-K and shall not be deemed to be "filed": Exhibit No. Exhibit Description 99.1 Press release dated July 23, 2024, issued by Strata Skin Sciences, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. STRATA SKIN SCIENCES, INC. Date: July 23, 2024 By: /s/ Christopher Lesovitz Christopher Lesovitz Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR